2304例接受CD19 CAR-T临床试验的大B细胞淋巴瘤患者的缓解与种族及临床决定因素
该研究汇总9项CAR-T临床试验共2304例B细胞淋巴瘤患者数据,其中395例(17.1%)筛选失败,1637例被分配CAR-T,151例(9.22%)因不良事件、疾病进展或死亡未接受治疗,1年生存率仅12%。对接受治疗者分析大B细胞淋巴瘤(LBCL,n=958)和惰性B细胞淋巴瘤(iBCL,n=349)两个队列,多因素Cox模型显示低体能状态和高肿瘤负荷(ECOG≥2、大包块疾病、桥接治疗)负向影响LBCL的总生存(OS)和无进展生存(PFS),而年龄和较短诊断至输注时间负向影响iBCL的OS和PFS。尽管非白人群体在所有试验阶段代表性不足,CAR-T治疗的可行性和有效性在种族和族裔群体间保持一致。
要点
- 筛选失败率17.1%,分配CAR-T者中9.22%未接受治疗,1年生存率仅12%。
- LBCL中ECOG≥2、大包块疾病和桥接治疗负向影响OS和PFS。
- iBCL中年龄和较短诊断至输注时间负向影响OS和PFS。
核心结论
- 尽管非白人群体在所有试验阶段代表性不足,CAR-T治疗的可行性和有效性在种族和族裔群体间保持一致。
- 低体能状态和高肿瘤负荷负向影响LBCL的OS和PFS,年龄和较短诊断至输注时间负向影响iBCL的OS和PFS。
研究设计与样本
- 汇总9项CAR-T临床试验共2304例B细胞淋巴瘤患者数据,数据通过Medidata Clinical Cloud获取。
- 2304例中395例(17.1%)筛选失败,1637例被分配CAR-T,151例(9.22%)因不良事件、疾病进展或死亡未接受治疗,1年生存率仅12%。
- 对接受治疗者分析两个队列:大B细胞淋巴瘤(LBCL,n=958)和惰性B细胞淋巴瘤(iBCL,n=349)。
主要发现
- 多因素Cox模型显示,LBCL中低体能状态和高肿瘤负荷(ECOG≥2、大包块疾病、桥接治疗)负向影响OS和PFS。
- iBCL中年龄和较短诊断至输注时间负向影响OS和PFS。
- 尽管非白人群体在所有试验阶段代表性不足,CAR-T治疗的可行性和有效性在种族和族裔群体间保持一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR T) therapy has advanced treatment for B-cell lymphoma (BCL), but >50% of patients relapse. Predicting clinical outcomes based on features at CAR T infusion remains unclear, and most trials lack racial diversity, limiting understanding of its impact on outcomes. To address these challenges, we pooled data from 9 CAR T clinical trials, consisting of 2304 patients with BCL. The nature of this data set, made available through the Medidata Clinical Cloud, represents a large set of patient-level data aggregated over 9 clinical trials that has not been previously analyzed in this manner. Of the 2304 patients, 395 (17.1%) failed screening, and 1637 were assigned CAR T; 151 (9.22%) did not receive treatment due to adverse events, disease progression, or death, with only 12% surviving at 1 year. For treated patients, we analyzed 2 cohorts: large BCL (LBCL, n = 958) and indolent BCL (iBCL, n = 349). Multivariate Cox models revealed that low performance status and high tumor burden (Eastern Cooperative Oncology Group ≥2, bulky disease, bridging therapy) negatively affected overall survival (OS) and progression-free survival (PFS) in LBCL, whereas age and shorter time from diagnosis to infusion negatively impacted OS and PFS in iBCL. Despite the underrepresentation of non-White groups across all trial phases, the feasibility and effectiveness of CAR T therapy were consistent across racial and ethnic groups.
引用
- Kho SJ, Diamond S, Lafeuille P, et al. Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials. Blood Adv. 2026. PMID: 41201393. doi:10.1182/bloodadvances.2025016361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。